The Body a Tumor Lands In: Aging, Whole-Body Metabolism, and Cancer Susceptibility

Why Age is Cancer’s Strongest Risk Factor

More than 60% of cancers occur in people aged 60 and over. It is one of the most consistent findings in oncology, and the standard explanation—that mutations accumulate over decades until one cell finally crosses a line—is true but incomplete. Mutation burden alone doesn’t account for why damage a 35-year-old body clears without incident can become a tumor in a 70-year-old body. Both bodies acquire damage. Only one of them tends to lose control of it.

The difference lies substantially in metabolism, though not the metabolism of any individual cell. It lies in the metabolic state of the whole organism. Two recent papers, read together, trace that idea from one end to the other: from what aging does to the body’s fuel economy, to why that economy governs immune surveillance, to what the resulting environment looks like at single-cell resolution once a tumor actually forms.

Aging is a systemic metabolic event

Start with the machinery. In his 2026 systems-physiology review The Biological Limits of Tumor Starvation, Richard Z. Cheng maps what he calls the integrated host-tumor metabolic network, and the striking thing about that map is how little of it is local. The liver continuously adjusts gluconeogenesis, ketogenesis, lipid handling, and acute-phase protein output. Skeletal muscle takes up glucose, turns over amino acids, and secretes myokines. Adipose tissue stores and releases fatty acids and modulates inflammation. The endocrine system (insulin, glucagon, cortisol, growth hormone, IGF-1, thyroid hormones, sex steroids) sets fuel partitioning across the entire body. Mitochondria in every tissue convert all of it into usable energy. The circulation ties them together.

As Cheng puts it, nutrients are not delivered independently to any tissue; they are distributed through highly integrated systemic regulatory networks. And this network is not neutral about where fuel goes. It evolved under recurrent scarcity, and its priority is unambiguous: the primary objective of human metabolism is preservation of the organism, not maximization of nutrient delivery to any individual tissue.

Every component of that network changes with age. Mitochondrial efficiency declines across brain, muscle, liver, and immune tissue. Insulin sensitivity falls and glucose handling shifts. Skeletal muscle mass, the body’s largest glucose sink and its amino acid reservoir, declines steadily after midlife. Adipose tissue redistributes and becomes a more active source of inflammatory signaling. Circulating hormone profiles shift. Baseline inflammatory tone rises, the phenomenon researchers call inflammaging.

None of this happens in tumors. It happens in people, and it happens well before any tumor exists.

Why a degraded fuel economy raises cancer risk

The link from that systemic drift to cancer susceptibility runs most directly through the immune system, because immune surveillance is among the most metabolically expensive things a body does.

Cheng puts the numbers in perspective. Activation of T lymphocytes, macrophages, dendritic cells, and natural killer cells requires profound metabolic reprogramming. Proliferation, cytokine synthesis, antigen presentation, phagocytosis, and cytotoxic killing all depend on adequate glucose, glutamine, amino acids, fatty acids, and mitochondrial ATP. During activation, many leukocytes increase glycolysis dramatically, reaching demands comparable to those of rapidly proliferating malignant cells.

Read that comparison in reverse, and its significance for aging becomes clear. An immune cell mounting an anti-tumor response is metabolically indistinguishable, in its appetite, from the cancer it is trying to kill. Anything that degrades the body’s capacity to fund that appetite degrades surveillance itself. Cheng’s conclusion in a therapeutic context applies just as well to a preventive one: preservation of immune competence is not supportive care at the margins. It is central.

This is why the metabolic changes of aging are not merely correlated with cancer. They plausibly produce susceptibility. A body with declining mitochondrial capacity, blunted insulin signaling, shrinking muscle reserve, and elevated inflammatory tone is a body less able to fund the expensive, sustained immune work that keeps early transformed cells from becoming clinical disease. The premalignant cell that a 35-year-old’s immune system eliminates without the person ever knowing is the same cell a 70-year-old’s immune system may lack the metabolic budget to finish off.

There is a second, subtler contribution. Cheng notes that the systemic regulatory machinery governing nutrient allocation evolved long before cancer became a major disease of aging. Those priorities were never tuned against neoplasia. A tumor competing for fuel inside an older body is competing against a system that is both less well-resourced and entirely indifferent to the contest.

What that body hands the tumor

Now suppose a cancer does develop. The systemic state that raised the risk doesn’t stop operating. It becomes the environment the tumor grows in. And this is where the second paper supplies remarkable detail.

In 2024, Chen and colleagues at Macau University of Science and Technology published a study in Cells screening 26 solid tumor types from The Cancer Genome Atlas and identifying 17 whose outcomes correlated with patient age. Using a computational framework called MMP³C, they compared the activity of 84 metabolic pathways (3,486 pathway pairs) across those cancers, then examined 181,286 individual cells from 24 glioblastoma patients grouped as young (under 50), middle (50 to 64), and aged (65 and over). What they found, in essence, is the fingerprint of an aged macroenvironment pressed into tumor tissue:

The energy tilt: Older patients’ tumors leaned harder on glycolysis while oxidative phosphorylation, the efficient mitochondrial route, was impaired. This is the Warburg effect, described by Otto Warburg in 1956, but here it deepens with the age of the host rather than appearing as a fixed property of malignancy. It is the same mitochondrial drift seen throughout aging tissue, showing up where a tumor happens to be.
The host’s own cells: At single-cell resolution, separating malignant from non-malignant populations in glioblastoma, it was the non-malignant cells in older patients that displayed the Warburg pattern, while malignant cells ramped up biosynthesis. The authors interpret this as a reverse Warburg effect: the host’s healthy tissue burning sugar and effectively supplying the tumor’s growth. The metabolic change was never confined to the cancer. It was in the tissue around it.
The immune ledger: In older patients, activated T cells and proinflammatory macrophages showed weakened energy-generating pathways, while the immune-regulatory FOLR+ macrophages enriched in aged tumors showed increased oxidative phosphorylation. The CD8+ T cells accumulating in aged tumors were pre-exhausted: rising glycolysis, declining mitochondrial output. Older patients had the fewest activated T cells of any age group; younger patients had more naïve and effector cells and more CCL3+ macrophages, a proinflammatory subtype with documented anti-cancer activity in glioma. This is precisely the metabolic budget problem described above, now visible cell by cell inside a tumor.
The systemic signature: The metabolic switches correlated significantly with molecular age markers, not just the calendar. And among the hub pathways anchoring the entire altered network sat oxidative phosphorylation, galactose metabolism, drug metabolism, tryptophan metabolism, and steroid hormone biosynthesis. Steroid hormones are systemic messengers by definition, manufactured and regulated at the level of the whole organism. Finding one anchoring a tumor’s metabolic architecture is a strong hint about where the controls live.

The Chen team is careful to note that their method identifies these shifts without establishing causes. But laid alongside Cheng’s physiology, the reading almost assembles itself. The tumor microenvironment in an older patient is not an independently generated ecosystem that happens to resemble an aged body. It is what a tumor’s neighborhood becomes when it forms inside one.

Why the direction of causation matters clinically

If the systemic state shapes the local one, then interventions aimed only at the local one are working downstream of what matters. This is Cheng’s central practical argument, and he grounds it in three constraints that operate together:

Shared metabolism limits selectivity: cancer cells arise from host tissue and retain nearly all the metabolic machinery of human life, so no major nutrient class is uniquely required by cancer.
Tumor plasticity limits durability: restrict one fuel and some tumors switch to glutamine, fatty acids, lactate, acetate, ketone bodies, or branched-chain amino acids, while every intervention acts as an evolutionary filter selecting for the cells that adapt.
Host physiology limits intensity: when intake falls, the body mobilizes glycogen, raises gluconeogenesis, releases fatty acids, accelerates ketogenesis, and redirects fuel to essential organs, defending itself and incidentally sustaining conditions the tumor can still exploit.

Together these produce a therapeutic window rather than a dose-response line. Tumor control improves with metabolic stress and then plateaus. Host physiological cost rises slowly at first, then accelerates as reserve is consumed. Past a point, more restriction buys less tumor control at steeply rising cost. Cheng notes that the boundary itself varies by age, nutritional status, organ function, inflammatory state, and individual metabolic resilience. Older patients have already spent much of the reserve that defines it.

His reframe follows directly, and it is the operative idea here: the goal is not maximal nutrient deprivation but maximal therapeutic differential, the largest achievable gap between metabolic stress on the tumor and metabolic stress on the host. That gap can be widened from either side. Strengthening the host is not a consolation prize when tumor-directed metabolic strategies hit their ceiling. It is the other half of the same equation.

Tending the macroenvironment

This makes the practical list less dramatic than starving cancer, and considerably better supported. Cheng’s own proposal for what should be measured alongside tumor response doubles as a reasonable guide to what deserves attention long before any diagnosis: immune competence, nutritional status, skeletal muscle preservation, metabolic health, functional capacity, quality of life, and treatment tolerance:

Preserve skeletal muscle: Muscle is a major metabolic organ, an amino acid reservoir, an endocrine tissue, and the determinant of physical resilience. Its loss during treatment is associated with worse survival and worse tolerance of therapy, and the decline begins decades earlier. Resistance training remains the only reliable way to rebuild it.
Protect insulin sensitivity: Insulin and IGF-1 are systemic growth signals reaching every tissue. Improving sensitivity through activity, sleep, and body composition changes the signaling environment in a way no local intervention can.
Eat adequately, particularly with age: Cancer cachexia is not uncomplicated starvation: it involves persistent inflammation, endocrine dysregulation, and accelerated protein catabolism that nutritional support alone cannot fully reverse. Older adults also use dietary protein less efficiently. The instinct to restrict deserves real scrutiny in the people with the least reserve to spend.
Address chronic inflammation at its sources: This includes sleep debt, visceral adiposity, sedentary behavior, and untreated metabolic disease, rather than expecting local immunity to function well inside a body running a constant inflammatory signal.
Support mitochondrial function systemically: Aerobic exercise remains the most robust available stimulus for mitochondrial biogenesis, and its effects are body-wide.

None of this treats cancer, and none of it substitutes for oncologic care. What it does is maintain the system that determines both how likely a cancer is to establish itself and what kind of ground it finds if it does.

One variable, read twice

The most useful thing about putting these two papers side by side is that they describe the same underlying variable at two different moments.

Before cancer, the body’s metabolic state determines how well it can fund the immune work that keeps transformed cells in check. That is susceptibility. After cancer, the same state determines the fuel, the signaling, and the immune capacity available in the tissue where the tumor sits. That is the microenvironment. They are not two problems. They are one condition, observed before and after a threshold.

Which suggests the question worth asking about age-related cancer risk is not only what is happening inside a tumor, but what kind of body a tumor would find itself in, and whether that body still has the metabolic capacity to fight.

References

The Body a Tumor Lands In: Aging, Whole-Body Metabolism, and Cancer Susceptibility

Dr. Daniel Thomas, DO, MS